Program: Education Program
Session: How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma? CAR T-Cells and Bispecific Antibodies
Hematology Disease Topics & Pathways:
Research, clinical trials, Clinical Practice (Health Services and Quality), Clinical Research
Session: How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma? CAR T-Cells and Bispecific Antibodies
Hematology Disease Topics & Pathways:
Research, clinical trials, Clinical Practice (Health Services and Quality), Clinical Research
Monday, December 11, 2023, 10:30 AM-11:45 AM
Disclosures: Mailankody: OncLive: Honoraria; Physician Education Resource: Honoraria; Optum Oncology: Consultancy; MJH Life Sciences: Honoraria; Janssen Oncology: Consultancy; Legend Biotech: Consultancy; Caribou Therapeutics: Research Funding; Takeda Oncology: Research Funding; Fate Therapeutics: Research Funding; Bristol Myers Squibb: Research Funding; Allogene Therapeutics: Research Funding; Janssen Oncology: Research Funding.
OffLabel Disclosure: Use of ide-cel and cilta-cel in earlier lines of therapy and discussion of CART cell therapies that are currently being evaluated in ongoing clinical trials but not approved by the FDA